Evidence map›Paper›PMID 22302016›Full record

ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2012

Gene set analysis of survival following ovarian cancer implicates macrolide binding and intracellular signaling genes.

Brooke L Fridley, Gregory D Jenkins, Ya-Yu Tsai, Honglin Song, Kelly L Bolton, David Fenstermacher, Jonathan Tyrer, Susan J Ramus, Julie M Cunningham, Robert A Vierkant and 12 more

Open access · greenAbstract read
In one paragraph

Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Investigation of Exomic Variants Associated with Overall Survival in Ovarian Cancer.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2016
    Article
  3. Article
  4. Article
  5. Integrative gene set analysis: application to platinum pharmacogenomics.Omics : a journal of integrative biology · 2014
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 5 institutions in 2 countries.

Brooke L FridleyDepartments of Health Sciences Research, Mayo Clinic, Rochester, Minnesota 55905, USA. fridley.brooke@mayo.edu
Gregory D Jenkins
Ya-Yu Tsai
Honglin Song
Kelly L Bolton
David Fenstermacher
Jonathan Tyrer
Susan J Ramus
Julie M Cunningham
Robert A Vierkant
Zhihua Chen
Y Ann Chen
Ed Iversen
Usha Menon
Aleksandra Gentry-Maharaj
Joellen Schildkraut
Rebecca Sutphen
Simon A Gayther
Lynn C Hartmann
Paul D P Pharoah
Thomas A Sellers
Ellen L Goode
Moffitt Cancer Center · USUniversity College London · GBMayo Clinic in Florida · USUniversity of Southern California · USDuke University · US

Funding

Use of microfluidic tumor cultures to enable clinical trials of therapies for ovarian cancerP50CA136393 · NCI · MAYO CLINIC ROCHESTER · PI Zhenkun Lou · 2009 to 2026
$37.0M
Ovarian cancer GWAS discovery, expansion and replication (N2 - Project #1)U19CA148112 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI SELLERS, THOMAS A · 2010 to 2014
$10.2M
Haplotype-Based Genome Screen for Ovarian Cancer LociR01CA114343 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI SELLERS, THOMAS A · 2007 to 2011
$7.5M
Population-Based Analysis of Ovarian Cancer BiomarkersR01CA106414 · NCI · UNIVERSITY OF SOUTH FLORIDA · PI SUTPHEN, REBECCA · 2005 to 2009
$3.0M
Genetic Variation in the NF-kappaB Pathway and Ovarian Cancer EtiologyR01CA122443 · NCI · MAYO CLINIC ROCHESTER · PI GOODE, ELLEN L. · 2007 to 2012
$2.7M
Integrative genomic models for analysis of pharmacogenomic studiesR21CA140879 · NCI · MAYO CLINIC ROCHESTER · PI FRIDLEY, BROOKE L · 2009 to 2010
$299k
Bayesian hierarchical nonlinear models for pharmacogenomic cytotoxicity studiesR21GM086689 · NIGMS · UNIVERSITY OF KANSAS MEDICAL CENTER · PI FRIDLEY, BROOKE L · 2011 to 2012
$232k
Cancer Research UK 10119Cancer Research UK 10124Cancer Research UK A10119Cancer Research UK C490/A10119NCI NIH HHS CA114343NCI NIH HHS CA122443NCI NIH HHS CA136393NCI NIH HHS CA140879NCI NIH HHS CA148112NCI NIH HHS P50 CA136393NCI NIH HHS R01 CA106414NCI NIH HHS R01 CA114343NCI NIH HHS R01 CA122443NCI NIH HHS R21 CA140879NCI NIH HHS U19 CA148112NIGMS NIH HHS GM86689NIGMS NIH HHS R21 GM086689
6 · The paper itself

Abstract

backgroundGenome-wide association studies (GWAS) for epithelial ovarian cancer (EOC), the most lethal gynecologic malignancy, have identified novel susceptibility loci. GWAS for survival after EOC have had more limited success. The association of each single-nucleotide polymorphism (SNP) individually may not be well suited to detect small effects of multiple SNPs, such as those operating within the same biologic pathway. Gene set analysis (GSA) overcomes this limitation by assessing overall evidence for association of a phenotype with all measured variation in a set of genes.

methodsTo determine gene sets associated with EOC overall survival, we conducted GSA using data from two large GWAS (N cases = 2,813, N deaths = 1,116), with a novel Principal Component-Gamma GSA method. Analysis was completed for all cases and then separately for high-grade serous histologic subtype.

resultsAnalysis of the high-grade serous subjects resulted in 43 gene sets with P < 0.005 (1.7%); of these, 21 gene sets had P < 0.10 in both GWAS, including intracellular signaling pathway (P = 7.3 × 10(-5)) and macrolide binding (P = 6.2 × 10(-4)) gene sets. The top gene sets in analysis of all cases were meiotic mismatch repair (P = 6.3 × 10(-4)) and macrolide binding (P = 1.0 × 10(-3)). Of 18 gene sets with P < 0.005 (0.7%), eight had P < 0.10 in both GWAS.

conclusionThis research detected novel gene sets associated with EOC survival. IMPACT: Novel gene sets associated with EOC survival might lead to new insights and avenues for development of novel therapies for EOC and pharmacogenomic studies.

Indexed as

Gene Expression ProfilingGenome-Wide Association StudyAdenocarcinoma, Clear CellAdenocarcinoma, MucinousBiomarkers, TumorCase-Control StudiesCystadenocarcinoma, SerousDisease SusceptibilityEndometrial NeoplasmsFemaleFollow-Up StudiesGenetic Predisposition to DiseaseHumansMiddle AgedNeoplasm GradingNeoplasm InvasivenessBiomarkers, Tumor

Identifiers

PMID22302016
PMCPMC3297690
OpenAlexW2170566269

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.